PL431445A1 - Rekombinowany polipeptyd do zastosowania jako lek, środek antyseptyczny, środek przeciwbakteryjny, środek przeciwzapalny, kompozycje go zawierające oraz jego zastosowania - Google Patents

Rekombinowany polipeptyd do zastosowania jako lek, środek antyseptyczny, środek przeciwbakteryjny, środek przeciwzapalny, kompozycje go zawierające oraz jego zastosowania

Info

Publication number
PL431445A1
PL431445A1 PL431445A PL43144519A PL431445A1 PL 431445 A1 PL431445 A1 PL 431445A1 PL 431445 A PL431445 A PL 431445A PL 43144519 A PL43144519 A PL 43144519A PL 431445 A1 PL431445 A1 PL 431445A1
Authority
PL
Poland
Prior art keywords
recombinant polypeptide
antiseptic
drug
inflammatory
antimicrobial
Prior art date
Application number
PL431445A
Other languages
English (en)
Other versions
PL243303B1 (pl
Inventor
Izabela SABAŁA
Elżbieta JAGIELSKA
Beata KUCZYŃSKA
Weronika AUGUSTYNIAK
Paweł MITKOWSKI
Alicja WYSOCKA
Original Assignee
Międzynarodowy Instytut Biologii Molekularnej I Komórkowej
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Międzynarodowy Instytut Biologii Molekularnej I Komórkowej filed Critical Międzynarodowy Instytut Biologii Molekularnej I Komórkowej
Priority to PL431445A priority Critical patent/PL243303B1/pl
Priority to PCT/PL2020/050075 priority patent/WO2021075988A1/en
Priority to CA3158146A priority patent/CA3158146A1/en
Priority to US17/768,608 priority patent/US20240409910A1/en
Priority to EP20819907.5A priority patent/EP4041286B1/en
Publication of PL431445A1 publication Critical patent/PL431445A1/pl
Publication of PL243303B1 publication Critical patent/PL243303B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/50—Isolated enzymes; Isolated proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24075—Lysostaphin (3.4.24.75)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Environmental Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Birds (AREA)
  • Dentistry (AREA)
  • Virology (AREA)
  • Agronomy & Crop Science (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Przedmiotem zgłoszenia jest rekombinowany polipeptyd zawierający: (i) domenę katalityczną LytM (LytMCD) zawierającą sekwencję aminokwasową przedstawioną w SEQ ID NO: 1 lub mającą z nią co najmniej 80% identyczności, (ii) domenę lizostafiny wiążącą ścianę komórkową bakterii (LssCWT), zawierającą sekwencję aminokwasową przedstawioną w SEQ ID NO: 2 lub mającą z nią co najmniej 80% identyczności, i (iii) opcjonalnie łącznik peptydowy łączący domenę katalityczną LytM i domenę lizostafiny wiążącą ścianę komórkową bakterii, a także jego zastosowanie jako lek, środek antyseptyczny, środek przeciwbakteryjny i/lub środek przeciwzapalny. Przedmiotem zgłoszenia jest także kompozycja weterynaryjna zawierająca powyższy polipeptyd, oraz kompozycja kosmetyczna lub pielęgnacyjna zawierająca rekombinowany polipeptyd.
PL431445A 2019-10-13 2019-10-13 Rekombinowany polipeptyd do zastosowania do leczenia, kompozycje go zawierające oraz jego zastosowania PL243303B1 (pl)

Priority Applications (5)

Application Number Priority Date Filing Date Title
PL431445A PL243303B1 (pl) 2019-10-13 2019-10-13 Rekombinowany polipeptyd do zastosowania do leczenia, kompozycje go zawierające oraz jego zastosowania
PCT/PL2020/050075 WO2021075988A1 (en) 2019-10-13 2020-10-13 Recombinant polypeptide for use as a medicine, antiseptic agent, antibacterial agent, anti-inflammatory agent, compositions comprising it and uses thereof
CA3158146A CA3158146A1 (en) 2019-10-13 2020-10-13 Recombinant polypeptide for use as a medicine, antiseptic agent, antibacterial agent, anti-inflammatory agent, compositions comprising it and uses thereof
US17/768,608 US20240409910A1 (en) 2019-10-13 2020-10-13 Recombinant polypeptide for use as a medicine, antiseptic agent, antibacterial agent, anti-inflammatory agent, compositions comprising it and uses thereof
EP20819907.5A EP4041286B1 (en) 2019-10-13 2020-10-13 Recombinant polypeptide for use as a medicine, antiseptic agent, antibacterial agent, anti-inflammatory agent, compositions comprising it and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL431445A PL243303B1 (pl) 2019-10-13 2019-10-13 Rekombinowany polipeptyd do zastosowania do leczenia, kompozycje go zawierające oraz jego zastosowania

Publications (2)

Publication Number Publication Date
PL431445A1 true PL431445A1 (pl) 2021-04-19
PL243303B1 PL243303B1 (pl) 2023-07-31

Family

ID=73699378

Family Applications (1)

Application Number Title Priority Date Filing Date
PL431445A PL243303B1 (pl) 2019-10-13 2019-10-13 Rekombinowany polipeptyd do zastosowania do leczenia, kompozycje go zawierające oraz jego zastosowania

Country Status (5)

Country Link
US (1) US20240409910A1 (pl)
EP (1) EP4041286B1 (pl)
CA (1) CA3158146A1 (pl)
PL (1) PL243303B1 (pl)
WO (1) WO2021075988A1 (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL243304B1 (pl) 2021-07-09 2023-07-31 Miedzynarodowy Inst Biologii Molekularnej I Komorkowej W Warszawie Hydrolaza peptydoglikanowa, kompozycje ją obejmujące, jej zastosowania oraz sposób hydrolizy ją wykorzystujący
CN113827701B (zh) * 2021-11-08 2022-05-20 北京芳渟阳生生物科技有限公司 抑制烫伤病菌的多肽在制备化妆品或药物组合物中的用途
PL449075A1 (pl) * 2024-06-29 2026-01-05 Instytut Medycyny Doświadczalnej I Klinicznej Im. M. Mossakowskiego Polskiej Akademii Nauk Rekombinowane białko hydrolazy peptydoglikanowej o właściwościach przeciwbakteryjnych, kompozycje je zawierające, ich zastosowania oraz sposoby je wykorzystujące

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103436507B (zh) * 2006-05-05 2016-04-20 冈戈根股份有限公司 噬菌体衍生的抗微生物活性剂
US8383102B2 (en) * 2009-05-21 2013-02-26 The United States Of America As Represented By The Secretary Of Agriculture Fusion of peptidoglycan hydrolase enzymes to a protein transduction domain allows eradication of both extracellular and intracellular gram positive pathogens

Also Published As

Publication number Publication date
PL243303B1 (pl) 2023-07-31
EP4041286B1 (en) 2026-07-15
CA3158146A1 (en) 2021-04-22
US20240409910A1 (en) 2024-12-12
EP4041286A1 (en) 2022-08-17
WO2021075988A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
ZA202109124B (en) Compounds targeting proteins and pharmaceutical compositions thereof, and their therapeutic applications
WO2008118017A3 (en) Prame derived peptides and immunogenic compositions comprising these
PH12020551205A1 (en) Fap inhibitors
TNSN07020A1 (en) Her2 antibody composition
WO2008057463A3 (en) Peptide-based conditioners
PL374608A1 (pl) Formulacja polipeptydowa
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
MEP25008A (en) Topical methadone compositions and methods for using the same
EP2189471A4 (en) FOXM1 PEPTIDE AND MEDICAMENT THEREFOR
MX2021009696A (es) Vectores de genoterapia para el tratamiento de la enfermedad de danon.
EP4253406A3 (en) Novel polypeptides and medical uses thereof
WO2021123911A3 (en) Nonionic polymeric fatty acid compounds for the treatment of fibrous amino acid-based substrates, especially hair
EA202091318A1 (ru) Препарат, содержащий аденовирус группы b
MY201355A (en) "compositions comprising amino acids for use in the prevention and treatment of liver diseases"
EA202190310A1 (ru) Белок для лечения воспалительных заболеваний
EA201991015A1 (ru) Модифицированные пептиды
WO2022058147A3 (de) Mittel zur oxidativen farbveränderung von keratinischen fasern mit komplexbildner und aminosäure und/oder proteinhydrolysat
FR2846883B1 (fr) Composition cosmetique comprenant, comme ingredient actif, au moins un peptide et utilisation de ce peptide
PH12021551659A1 (en) Oral care preparations comprising chlorhexidine and arginine or their salts
MX2022008748A (es) Administración oral de péptidos.
BR112022005782A2 (pt) Proteína galectina 9 estabilizada recombinante, vetor recombinante, transformante, composição farmacêutica para prevenção ou tratamento de uma doença óssea, alimento funcional de saúde para prevenção ou melhora de uma doença óssea, e, uso de uma proteína galectina 9 estabilizada recombinante
BR112022003359A2 (pt) Composição de amida peptídica e método de preparação da mesma
JOP20240271A1 (ar) ببتيدات إظهار أنشطة منع فقدان العضلات وتعزيز الكتلة العضلية واستخداماتها
CL2022000990A1 (es) Combinación de un antagonista de cxcr7 con un modulador del receptor s1p1
BR0109279A (pt) Antagonistas de lhrh, sua preparação e aplicação como medicamento